Introduction {#S1}
============

Natural killer (NK) cells belong to the family of innate lymphoid cells (ILCs) whose common features include reliance on the transcription factor ID2 for development and rapid elaboration of effector function in response to microbial products, cytokine stimulation, and contact with other leukocytes ([@B1]). ILCs share phenotypic and functional features with T cells, yet, ILCs lack expression of markers specific for other leukocytes, including antigen-specific T and B cell receptors (i.e., CD3/TCR and CD19/BCR). In 2013, Spits et al. published a proposal for ILC nomenclature and classification, including the designation of three major groups according to functional and phenotypic characteristics ([@B2]). Group 1 ILCs, which express the transcription factor T-BET and produce the T helper cell type 1 (Th1)-associated cytokine interferon gamma (IFN-γ), include NK cells as well as functionally distinct "ILC1s." NK cells are unique in their expression of the transcription factor EOMES and in their ability to recognize and destroy virally infected and malignantly transformed cells that have downregulated major histocompatibility (MHC) class I molecules and/or upregulated stress-induced molecules ([@B3], [@B4]). Group 2 ILCs or "ILC2s" produce Th2-associated cytokines, such as interleukin (IL)-5 and IL-13; they express the transcription factors BCL11B, GATA-3, and RORα; and they are involved in many processes, including fat metabolism, allergy, and protection against parasites ([@B5]). Group 3 ILCs share features with Th17 cells, including expression of the transcription factors AHR and RORγt and production of IL-17 and IL-22. Group 3 ILCs consist of "ILC3s" as well as lymphoid tissue inducer cells whose roles include the formation and restoration of lymphoid tissues following infection ([@B6]). We refer the readers to other excellent comprehensive reviews exploring the development, transcriptional regulation, and diverse roles of ILCs in physiology and disease ([@B1], [@B7]--[@B12]).

As mentioned above, ILCs are identified as "lineage" (Lin) negative lymphocytes, lacking expression of surface markers more specifically expressed on T cells (CD3, CD5, TCR), B cells (CD19, CD20, BCR), myelomonocytic cells (CD14, CD15, CD36), and dendritic cells (DCs) (CD116, CD123, CD303). In humans, all non-NK ILCs express CD127 (IL-7Rα) and CD161 (NKRP1A) ([@B13]--[@B16]), and they may be further distinguished according to the expression of other subset-associated surface antigens including CXCR3, CD294 (CRTH2), and CD117 (c-Kit) for ILC1s, ILC2s, and ILC3s, respectively ([@B10], [@B17]). Human NK cells can also express the pan-ILC markers CD127 and CD161 ([@B18]--[@B20]), but NK cells are typically distinguished by their surface expression of CD16 (FcγRIIIA), CD94/NKG2 heterodimers, killer immunoglobulin-like receptors (KIRs), NKG2D, and NKp80 ([@B21]). Two subsets of human peripheral blood (PB) NK cells can be distinguished according to their relative expression of the pan-NK cell surface marker, CD56 (NCAM-1): "CD56^bright^" and "CD56^dim^" ([@B22], [@B23]). CD56^bright^ human NK cells express high levels of CD62L ([l]{.smallcaps}-selectin) and CD94 but absent or low levels of CD16 and KIRs; they predominate in secondary lymphoid tissues (SLTs) such as lymph nodes (LNs) and tonsils; they show low baseline perforin expression and cytotoxic activity *ex vivo*; and they rapidly produce cytokines, including IFN-γ, following stimulation by monocyte-derived cytokines ("monokines"), such as IL-12, IL-15, and IL-18 ([@B22]). In contrast, CD56^dim^ NK cells are CD16^hi^ and express more KIRs but less CD94 and CD62L; they predominate in PB; they show high baseline perforin expression and cytotoxicity against MHC class I negative target cells; and they preferentially produce cytokines in response to direct target cell interactions rather than *via* monokine stimulation ([@B3]). While the developmental relationship between these human NK cell subsets has not been definitively established, evidence suggests that CD56^bright^ NK cells represent immediate physiologic precursors of CD56^dim^ NK cells ([@B19], [@B24]--[@B29]). Alternative hypotheses include that CD56^bright^ NK cells represent activated NK cells *in vivo* and/or that PB NK cell subsets derive from distinct hematopoietic progenitor cells (HPCs) and developmental pathways ([@B22], [@B30]--[@B33]). Recent published data from Dunbar and colleagues suggest that the latter may be the case in rhesus macaques ([@B34]).

Human NK Cell Development in SLTs {#S2}
=================================

Human NK cells were originally thought to develop strictly within the bone marrow (BM) ([@B3], [@B35]). This notion was supported by the observation that Lin^−^CD56^+^ cytotoxic NK cells can be generated *in vitro* following culture of purified human BM CD34^+^ HPCs with either BM-derived stroma or with IL-15, which can be produced by stroma ([@B36], [@B37]). Nonetheless, more recent extensive *ex vivo* characterization of HPCs and putative downstream NK cell developmental intermediates (NKDIs) reveals that the latter are naturally enriched in SLTs, including tonsils, spleen, and LNs, suggesting that in humans NK cells can also, if not preferentially, develop in SLTs (Figure [1](#F1){ref-type="fig"}A) ([@B38]--[@B42]). Similar NKDIs have also been identified in the thymus, liver, and uterus ([@B43]--[@B45]). Thus, human NK cell development is likely not restricted to SLTs ([@B46]).

![***Ex vivo* patterns of surface antigen expression support a model of human natural killer (NK) cell development in secondary lymphoid tissues (SLTs)**. **(A)** *Ex vivo* immunophenotypic analyses of CD3^+^ cells (top row, left plots), CD19^+^ cells (top row, right plots), and Lin^−^CD56^+^ cells (bottom row) in the indicated tissues demonstrate how immature T, B, and NK cell developmental intermediates (designated by the red circles and ovals) are naturally enriched in the thymus, bone marrow, and SLTs, respectively. Of note, the SLT populations designated by the red circles in the bottom row also likely contain some ILC3s, which can express CD56 ([@B14]). The red arrows in the bottom row highlight the relative enrichment of stage 4b CD56^bright^NKp80^+^CD16^−^ NK cells in SLTs. **(B)** Immunophenotypic analysis of Lin^−^ ILCs in human tonsil demonstrating the two-way patterns of CD34, CD117, CD94, NKp80, and CD16 expression as they relate to one another. The red arrows depict the putative directions of progressive NK cell development in SLTs. **(C)** Schematic representation of the proposed stages of human NK cell development in SLTs. The stages are defined according to the differential expression of CD34, CD117, interleukin (IL)-1R1, CD94, NKp80, CD16, and CD57, and the red lines underline the surface antigen changes that define each stage transition. Although not depicted, it is noted that CD56 expression is first detected at stage 2b (heterogeneous), peaks at stage 4b (CD56^bright^), and then decreases to the level of most peripheral blood NK cells at stage 6 (CD56^dim^). Also not depicted is killer immunoglobulin-like receptor expression, which is first detected within stage 4b in SLTs ([@B40]).](fimmu-08-00360-g001){#F1}

In 2006, five putative stages of human SLT NK cell development were described according to the differential expression of CD34, CD117, CD94, and CD16 ([@B41], [@B47], [@B48]). Stage 1 cells (Lin^−^CD34^+^CD117^−^CD94^−^CD16^−^) lack expression of the common IL-2/IL-15 receptor beta chain (IL-2/15Rβ, CD122) and are thus not responsive to exogenous soluble IL-2 or IL-15 *ex vivo*. However, they can generate NK cells when cultured in IL-15 plus other cytokines, such as Flt3 ligand and c-Kit ligand (KL) that likely induce CD122 expression and hence IL-15 responsiveness ([@B49]). In contrast, stage 2 cells (Lin^−^CD34^+^CD117^+^CD94^−^CD16^−^) constitutively express CD122 (albeit below the level of detection by flow cytometry) and can generate functionally mature NK cells *in vitro* in the presence of exogenous soluble IL-15 in media without other cytokines or support cells ([@B41]). Stage 2 cells also constitutively express a functional high affinity IL-2 receptor, including the IL-2Rα subunit (CD25), and can differentiate in response to picomolar concentrations of IL-2 *in vitro* ([@B39]). The physiologic relevance of this cytokine receptor expression is not yet known and has not been tested *in vivo*. One likely possibility is that these HPCs, which are naturally enriched and reside within the parafollicular T cell-rich regions of SLTs, can respond to T cell-derived IL-2 and differentiate into NK cells following T cell activation *in vivo* ([@B39]).

When originally tested in bulk polyclonal cultures under supportive *in vitro* conditions, stage 1 and stage 2 cells were multipotent and could give rise to T cells and DCs as well as to NK cells, although they could not generate B cells or myeloid cells ([@B41]). In contrast, human stage 3 cells (Lin^−^CD34^−^CD117^+^CD94^−^CD16^−^) lacked T cell and DC developmental potential. Stage 3 cells could, however, give rise to mature NK cells *in vitro* and *in vivo* and were thus originally proposed to represent committed NK cell precursors ([@B41]). Stage 3 cells are distinct from mature NK cells in that they lack high expression of T-BET and EOMES, cannot produce IFN-γ, and are incapable of mediating perforin-dependent cytotoxicity against MHC class I^−^ target cells. In contrast, these features are detected within the stage 4 (CD34^−^CD117^+/−^CD94^+^CD16^−^) and stage 5 (CD34^−^CD117^lo/−^CD94^+/−^CD16^+^) populations in SLTs ([@B40], [@B41]). Stage 5 cells are further distinguished by the constitutive expression of CD16, a low affinity receptor for the Fc portion of immunoglobulin, which provides for antibody-mediated cellular cytotoxicity ([@B50]).

Recent Advances in Our Understanding of Human NKDIs {#S3}
===================================================

Continued *ex vivo* phenotypic and functional characterization of the aforementioned five putative NKDI populations in human SLTs has revealed a remarkable degree of heterogeneity within each stage. For example, in a study comparing tonsil- and thymus-derived HPCs, McClory et al. demonstrated that the human SLT stage 1 population, which expresses CD45RA and CD10, contains a minute subset of CD1a^+^CD11c^−^ cells that gives rise to T cells *ex vivo* and that shows substantial phenotypic overlap with CD34^+^CD45RA^+^CD10^+^CD1a^+^ T cell precursors in the thymus ([@B51]). McClory et al. were also able to trace a full putative pathway of tonsil T cell development branching directly from the tonsil CD34^+^CD45RA^+^CD10^+^CD1a^+^CD11c^−^ stage 1 subset and closely paralleling T cell development in the thymus. These data suggest that the developmental pathways of other lymphoid subsets overlap/intersect with the originally characterized NK cell developmental pathway in SLTs. Consistent with this notion, Montaldo et al. recently showed that human SLT-derived stage 2 cells constitutively express RORγt and can give rise to RORγt^+^CD117^+^ ILC3s ([@B52]). In that study, Montaldo et al. observed relatively low NK cell production from stage 2 cells under the *in vitro* conditions tested. Given those findings, the investigators concluded that the stage 2 cells represent lineage-specified ILC3 progenitors. However, Montaldo et al. did not assess for the capacity of stage 2 cells to differentiate into other lineages such as DCs and T cells, and as mentioned earlier, Freud et al. demonstrated that stage 2 cells can differentiate into T cells, DCs, and NK cells under supportive conditions ([@B41]).

In a subsequent study, Scoville et al. characterized two functionally distinct subsets of SLT stage 2 cells according to surface expression of the IL-1β receptor, IL-1R1 ([@B42]). Both IL-1R1^−^ (i.e., stage "2a") and IL-1R1^+^ (i.e., stage "2b") subsets express CD45RA, integrin β7, and *ID2*, and they show low or undetectable expression of CD10. However, the stage 2b cells are unique in their near uniform expression of the pan-ILC marker, CD161, their lack of detectable expression of *RAG1* mRNA, which is expressed in stage 1 and stage 2a cells, and their natural restriction to SLTs. In a series of experiments in which stage 1, stage 2a, and stage 2b cells were freshly purified and then cultured *in vitro* or transplanted into non-obese diabetic (NOD)-scid IL2Rgamma^null^ (NSG) immunodeficient mice treated with human IL-15, the stage 2b population was shown to be capable of giving rise to all four major subsets of ILCs (ILC1s, ILC2s, ILC3s, and NK cells), yet, they lacked T cell and DC developmental potential. In contrast, stage 1 and stage 2a cells could give rise to all ILC subsets as well as to T cells and DCs under the conditions tested ([@B42]). Thus, stage 2b cells appear to represent common ILC progenitors (CILPs) in humans.

Following the original discovery of SLT stage 3 cells ([@B41]), it was determined that cells within this population (Lin^−^CD34^−^CD117^+^CD94^−^CD16^−^) express AHR, CD127, RORγt, IL-1R1, and IL-22 ([@B14], [@B53]--[@B55]). According to the 2013 ILC classification, these features denote Group 3 ILCs ([@B2]). Thus, it is not yet clear if stage 3 cells and ILC3s are entirely overlapping in their phenotypic characteristics, and this is a subject of ongoing investigation (see below) ([@B56]). Within the stage 3/ILC3 population in human SLTs, there is marked heterogeneity with regards to the expression of numerous surface markers, including CD7, CD56, CD62L, HLA-DR, and NKp44 ([@B14], [@B41], [@B57], [@B58]). The significance of this heterogeneity is largely unknown, although it was shown that NKp44 expression closely correlates with IL-22 production *ex vivo* ([@B53], [@B58]).

Last, in a recent study by Freud and colleagues, the SLT stage 4 population, defined as Lin^−^CD34^−^CD117^+/−^CD94^+^CD16^−^, was shown to contain two functionally distinct subsets according to expression of the surface activating C-type lectin-like receptor, NKp80 ([@B40]), which is expressed on most if not all PB NK cells in healthy humans ([@B59]). Freud et al. described these SLT stage 4 subsets as stage "4a" (NKp80^−^) and stage "4b" (NKp80^+^), and they demonstrated that only the stage 4b subset is capable of IFN-γ production and perforin-dependent cellular cytotoxicity *ex vivo* ([@B40]). Consistent with these functional data, the surface expression of NKp80 among total SLT ILCs closely correlates with intracellular expression of T-BET, EOMES, and perforin. In contrast to stage 4b cells, stage 4a cells, which express CD94/NKG2A, lack the aforementioned functional and phenotypic features associated with mature NK cells and rather show a stage 3/ILC3-like profile including expression of CD117, CD127, IL-1R1, AHR, RORγt, and IL-22 ([@B40]). Following co-culture with allogeneic monocyte-derived DCs or transplantation into NSG mice treated with IL-15, purified SLT stage 4a cells gave rise to functional NK cells including some that were NKp80^+^CD16^+^ and coexpressed KIRs and CD57, the latter of which has been associated with terminal maturation and may represent a putative "stage 6" of human NK cell development ([@B60], [@B61]). Thus, stage 4a cells appear to comprise a naturally occurring and physiologic developmental intermediate population of cells emerging from stage 3 cells and giving rise to stage 4b cells. This hypothesis is supported by *ex vivo* patterns of surface antigen expression among total Lin^−^ ILCs in human SLTs (Figure [1](#F1){ref-type="fig"}B).

Modeling Human NK Cell Development in the Context and Era of ILCs {#S4}
=================================================================

Collectively, these recently published data described above support an updated linear model of human NK cell development (Figure [1](#F1){ref-type="fig"}C), which incorporates SLT NKDIs as well as the putative progressive development of human PB NK cells from CD56^bright^CD94^+^NKp80^+^CD16^−^CD57^−^ (i.e., stage 4b) to CD56^dim^CD94^+/−^NKp80^+^CD16^+^CD57^−^ (i.e., stage 5) to CD56^dim^CD94^+/−^NKp80^+^CD16^+^CD57^+^ (i.e., stage 6). Although this is still somewhat controversial, a linear developmental relationship between PB CD56^bright^ and CD56^dim^ NK cell subsets is supported by the recent detection of PB NK cell populations that appear to represent naturally occurring NKDI spanning the developmental continuum between CD56^bright^ and CD56^dim^ NK cells ([@B27], [@B29]). In addition, other studies have shown that CD56^bright^ NK cells can give rise to CD56^dim^ NK cells *in vitro* and *in vivo* ([@B19], [@B24], [@B26]).

Despite the accumulating evidence in support of this proposed model, it is likely that other pathways of human NK cell development exist *in vivo* and potentially account for the marked diversity among tissue-resident NK cells ([@B62]--[@B64]). For example, Renoux et al. recently described a putative lineage committed NK cell progenitor (NKP) population in human BM, blood, and SLTs characterized as Lin^--^CD34^+^CD38^+^CD123^--^CD45RA^+^CD7^+^CD10^+^CD127^−^ and that could only give rise to NK cells *in vitro* and *in vivo* ([@B65]). Given that this NKP is only partially CD117^+^ and reportedly lacks detectable expression of CD161 and CD127, it appears to be distinct from the aforementioned SLT CILP (i.e., stage 2b) population that is CD117^+^CD161^+^CD127^+^ and that can generate all ILCs including NK cells ([@B42]). Rather, the immunophenotype of the NKP described in the study by Renoux et al. appears to overlap with that of the stage 1 and stage 2a populations described above. Indeed, it will be important in future studies to determine how these various HPC populations are related. Regardless, the study by Renoux et al. raises the intriguing possibility of other NK cell developmental pathways in humans.

It is also important to note that the human model of NK cell development depicted here differs from contemporary models of murine NK cell development (Figure [2](#F2){ref-type="fig"}) ([@B1], [@B7], [@B12]). Aside from inherent challenges in comparing these developmental processes due to differences in species-specific antigen expression, there may be fundamental differences between the species with regards to the developmental relationship(s) between NK cells and other ILCs and with regards to transcription factor expression patterns. For example, in mice, all ILC subsets are thought to derive from a CILP population that subsequently gives rise to committed NKPs as well as to common helper ILC progenitor cells (CHILPs) that can differentiate into ILC1s, ILC2s, and ILC3s, but not NK cells ([@B66]--[@B70]). While putative human CILPs (SLT stage 2b cells) and NKPs have been described as discussed above ([@B42], [@B65]), it is not yet clear if these two populations are related in the same way that the analogous populations in mice have been described. In addition, a human CHILP population has not been identified.

![**Models of mouse and human innate lymphoid cell (ILC) development**. Shown on the left and right are schematic representations of the cellular intermediates and developmental pathways of mouse and human ILCs, respectively. The black lines represent progressive steps of differentiation and maturation that are currently supported by published data. The dashed lines represent possible steps and relationships of differentiation and maturation, but these have not yet been tested or definitively established. In particular, the relationships between stage 1, 2a, 2b, and 3 cells with NK cell progenitors (NKPs) described by Renoux et al. ([@B65]) are not yet known. In addition, the relationship and possible distinction between human stage 3 natural killer (NK) cell precursors and ILC3s is also not yet clear. In the diagram to the right depicting human ILC development, the labels ILC3P (for ILC3 progenitor), ILC2P (for ILC2 progenitor), and ILC1P (for ILC1 progenitor) are shown in parentheses to convey that these are theoretical populations that have not been identified. CILP, common innate lymphoid progenitor; CHILP, common helper innate lymphoid progenitor.](fimmu-08-00360-g002){#F2}

Another potential difference between mouse and human NK cell development relates to the relationship between NK cells and ILC3s. In mice, these two ILC subsets appear to be developmentally distinct ([@B6]), because in addition to these CHILP data described above, genetic fate-mapping (fm) studies for *Rorc2*, which encodes Rorγt, showed that mouse ILC3s are *Rorc2* fm^+^ whereas mouse Eomes^+^ NK cells are *Rorc2* fm^−^ ([@B68], [@B71], [@B72]). In contrast, Scoville et al. recently demonstrated that the putative human CILP (SLT stage 2b) population expresses RORγt and that human PB CD56^bright^ NK cells, which are NKp80^+^EOMES^+^ ([@B4], [@B40], [@B59], [@B73], [@B74]), constitutively express detectable *RORC2* transcript ([@B42]). Thus, as opposed to mouse NK cells, at least some human NK cells would be fm^+^ for *RORC2* if such an experiment could be performed. In addition, as mentioned earlier, there is substantial phenotypic overlap between cells originally described as "stage 3" NK cell precursors and cells denoted as "ILC3s" by other groups, raising the question as to whether or not these cell types are different or comprise the same population in humans ([@B56]). To address this issue, Crellin et al. previously evaluated the *in vitro* differentiation potentials of Lin^−^CD34^−^CD161^+^CD117^+^ ILCs according to the differential expression of CD127 ([@B75]). They demonstrated that a minute CD127^−^ fraction preferentially gave rise to NK cells whereas the predominant CD127^+^ fraction mostly retained ILC3 features. Thus CD127 has since been touted as a critical marker distinguishing human stage 3 NK cell precursors from ILC3s ([@B1], [@B6]). However, in the study by Crellin et al., CD94^+^ NK cells, which can express CD117 and CD161 ([@B18], [@B76]), were not excluded in the pre-culture sorting preparations ([@B75]). Moreover, other reports suggest that the *in vitro* conditions used by Crellin et al. may be better optimized for supporting NK cell differentiation; conditions such as co-culture with OP9-DL1 stroma or DCs may be needed ([@B40], [@B42]). As such, the results provided in the Crellin et al. study could be due at least in part to the culture conditions employed and/or the preferential expansion of CD94^+^ NK cells that were present in the sorted Lin^−^CD34^−^CD161^+^CD117^+^CD127^−^ fractions. Last, we note that CD127 is constitutively expressed on PB CD56^bright^ NK cells ([@B19], [@B20]), and so excluding any CD127^+^ cells as potential NK cell precursors may be incorrect. Thus, to the best of our knowledge, there is as yet no reliable immunophenotypic strategy to distinguish human stage 3 NK cell precursors from ILC3s. Further investigation is needed.

Concluding Remarks and Future Directions {#S5}
========================================

The goals of investigating human NK cell development are to understand malignant counterparts and to facilitate the design and implementation of optimal immunotherapies for patients with cancer and potentially other diseases. Much progress has been made; however, the recent discovery of non-NK ILCs has required a reassessment of models of NK cell development in both mice and humans. More work is also needed in order to understand how all ILCs develop and to determine if the putative pathway of human NK cell development in SLTs is representative of NK cell development in other tissues.
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